| MeSH term | MeSH ID | Detail |
|---|---|---|
| Inflammatory Bowel Diseases | D015212 | 9 associated lipids |
| Reperfusion Injury | D015427 | 65 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Fatty Liver | D005234 | 48 associated lipids |
| Cataract | D002386 | 34 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Metalidis C et al. | Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. | 2011 | Transplantation | pmid:21544031 |
| Ekberg H | Calcineurin inhibitor sparing in renal transplantation. | 2008 | Transplantation | pmid:18813097 |
| Fischer L et al. | Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. | 2015 | Transplantation | pmid:26151607 |
| Keenan RJ et al. | Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. | 1991 | Transplantation | pmid:1719668 |
| Nakamura Y et al. | Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. | 2003 | Transplantation | pmid:12717187 |
| Calmus Y et al. | Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. | 2010 | Transplantation | pmid:20495510 |
| Ouyang J et al. | Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. | 2005 | Transplantation | pmid:15912108 |
| Egli A et al. | Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. | 2009 | Transplantation | pmid:19935369 |
| Boyer O et al. | Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. | 2005 | Transplantation | pmid:15912111 |
| Villanueva G and Baldwin D | Rosiglitazone therapy of posttransplant diabetes mellitus. | 2005 | Transplantation | pmid:16340782 |
| Numakura K et al. | Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. | 2005 | Transplantation | pmid:16340785 |
| Koneru B et al. | Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? | 1997 | Transplantation | pmid:9197350 |
| Sugitani A et al. | En bloc pancreas and kidney transplantation in a patient with limited vascular access. | 1997 | Transplantation | pmid:9197366 |
| Shihab FS et al. | Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. | 2009 | Transplantation | pmid:19202436 |
| Furukawa H et al. | The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. | 1992 | Transplantation | pmid:1373531 |
| Bierer BE et al. | Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. | 1990 | Transplantation | pmid:1694317 |
| Eiras G et al. | Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. | 1990 | Transplantation | pmid:1694318 |
| Sankary HN et al. | FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. | 1998 | Transplantation | pmid:9798690 |
| Pirsch JD et al. | A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. | 1997 | Transplantation | pmid:9112351 |
| Tanabe M et al. | Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. | 1994 | Transplantation | pmid:7518619 |
| Wang SC et al. | A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. | 1993 | Transplantation | pmid:7692640 |
| Bellon H et al. | The Effect of Immunosuppression on Airway Integrity. | 2017 | Transplantation | pmid:28471870 |
| Barten MJ et al. | Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. | 2004 | Transplantation | pmid:15114077 |
| Gruessner RW et al. | Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. | 1997 | Transplantation | pmid:9415558 |
| Couzi L et al. | Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. | 2008 | Transplantation | pmid:18946343 |
| Horner BM et al. | Recipient damage after musculocutaneous transplant rejection. | 2008 | Transplantation | pmid:18946349 |
| Kaufman DB et al. | The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. | 1995 | Transplantation | pmid:7541579 |
| Herzog D et al. | Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. | 2006 | Transplantation | pmid:16534467 |
| McDiarmid SV et al. | Factors affecting growth after pediatric liver transplantation. | 1999 | Transplantation | pmid:10030286 |
| Eckhoff DE et al. | The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. | 2000 | Transplantation | pmid:10830224 |
| Nakata Y et al. | Tacrolimus and myocardial hypertrophy. | 2000 | Transplantation | pmid:10830241 |
| Hanto DW and Chudzinski R | What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? | 2009 | Transplantation | pmid:19155968 |
| Ericzon BG et al. | Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. | 1997 | Transplantation | pmid:9000664 |
| Schena FP et al. | Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. | 2009 | Transplantation | pmid:19155978 |
| Opelz G and Döhler B | Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. | 2008 | Transplantation | pmid:18698238 |
| Tamura K et al. | Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. | 1995 | Transplantation | pmid:7539960 |
| Fisher A et al. | FK506 hepatotoxicity in liver allograft recipients. | 1995 | Transplantation | pmid:7539961 |
| Valdivia LA et al. | Dendritic cell replacement in long-surviving liver and cardiac xenografts. | 1993 | Transplantation | pmid:7689265 |
| Pape E et al. | Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. | 2015 | Transplantation | pmid:26308424 |
| Gruessner RW et al. | Donor-specific portal blood transfusion in intestinal transplantation: a prospective, preclinical large animal study. | 1998 | Transplantation | pmid:9701258 |
| Min SI et al. | CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. | 2010 | Transplantation | pmid:21076384 |
| Chan L et al. | Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. | 2008 | Transplantation | pmid:18360262 |
| Hricik DE et al. | Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. | 2002 | Transplantation | pmid:12151730 |
| Saad ER et al. | Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. | 2008 | Transplantation | pmid:18360267 |
| Warty V et al. | FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. | 1988 | Transplantation | pmid:2458643 |
| Tsugita M et al. | Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. | 1996 | Transplantation | pmid:8685952 |
| Hewitt CW and Black KS | Comparative studies of FK506 with cyclosporine. | 1988 | Transplantation | pmid:2458644 |
| Gruber SA and Doshi MD | Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. | 2010 | Transplantation | pmid:20440195 |
| Burger CI et al. | Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. | 2010 | Transplantation | pmid:20440199 |
| Wong W et al. | 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? | 2005 | Transplantation | pmid:16082321 |